石藥集團(01093.HK)上半年營收162.84億元 股東應占溢利超30億元
格隆匯8月21日丨石藥集團(01093.HK)公佈2024年中期業績,2024年上半年,收入為人民幣162.84億元,較去年同期增加1.3%。股東應占基本溢利為人民幣32.17億元,較去年同期增加1.7%。股東應占溢利為人民幣30.20億元,較去年同期增加1.8%。擬派中期股息每股16港仙。
2024年上半年,成藥業務錄得收入人民幣135.49億元,同比增長4.8%;原料產品業務錄得銷售收入人民幣18.55億元,同比減少5.8%;功能食品及其它業務錄得銷售收入人民幣8.80億元,同比減少25.2%,主要是受到咖啡因產品價格下跌的影響。
2024年上半年研發費用較去年同期增加10.3%至人民幣25.42億元,約佔成藥業務收入18.8%。目前逾60個重點在研藥物已進入臨牀或申報階段,其中7個已遞交上市申請,19個產品(22個適應症)處於註冊臨牀階段。
年初至今,於中國有2款創新藥(新增適應症)獲批上市,獲得22項臨牀試驗批准,5款仿製藥獲得藥品註冊批件;於北美地區有3款在研創新藥物獲得臨牀試驗批准。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.